Skip to content
lifestyle.thedishh.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Altesa Biosciences Inc.
Vapendavir Reduces Inflammation in COPD Patients: New Clinical Data
September 8, 2026
Altesa BioSciences Named Recipient of the 2026 Georgia Life Sciences Golden Helix Award for Financing Deal of the Year
August 25, 2026
Altesa BioSciences Appoints Brett Haumann, MBBCh, MBA, to its Board of Directors and Gwen Skloot, MD, ATSF, as Senior Vice President for Clinical Development
June 2, 2026
Altesa BioSciences Presents Positive Phase 2 Challenge Study Results for Vapendavir at American Thoracic Society International Conference 2026
May 19, 2026
New Altesa BioSciences Data: Vapendavir Demonstrates Anti-Viral Activity Against All Three Rhinovirus Species
May 12, 2026
Altesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir as Transformational Treatment for Patients with COPD Impacted by Rhinovirus, the Leading Cause of Exacerbations
May 5, 2026
Altesa BioSciences Selected for Oral Presentation at the American Thoracic Society 2026 International Congress
May 5, 2026
Altesa BioSciences’ Treatment for Rhinovirus Infections in People with Respiratory Conditions, Vapendavir, Selected for Oral Presentation at the International Society for Antiviral Research Conference (ICAR) 2026
April 29, 2026